The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country. Among the items that cannot be parallel exported from the UK as of 21 March are amoxicillin, paracetamol and insulin, as well as enoxaparin, heparin, hydrocortisone, morphine, ondansetron and proton pump inhibitors such as lansoprazole, omeprazole, and pantoprazole.
UK Blocks 82 From Parallel Export
BGMA Does Not Foresee Imminent Shortages Amid Coronavirus
The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country, including amoxicillin, insulin, paracetamol and several common proton pump inhibitors. The move comes as local off-patent industry association the BGMA has insisted that no short-term or medium-term shortages are foreseen amid the coronavirus pandemic.
More from Regulation
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
More from Policy & Regulation
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
• By
The FDA generic drugs team’s first public workshop of the second Trump Administration ended with a request that industry amplify the value it finds from public engagement.
• By
Generics Bulletin reviews global regulatory developments across the globe.